ライフサイエンスコーパス: carcinomatosis

1 l in a syngeneic model of ovarian peritoneal carcinomatosis.

2 esophageal cancer reduced LRR and peritoneal carcinomatosis.

3 tation, which invariably involves peritoneal carcinomatosis.

4 mmunotherapy" in a mouse model of peritoneal carcinomatosis.

5 to benefit selected patients with peritoneal carcinomatosis.

6 Cs) and their capacity to initiate an active carcinomatosis.

7 l tumor excision in patients with peritoneal carcinomatosis.

8 al cavity in a condition known as peritoneal carcinomatosis.

9 results in selected patients with peritoneal carcinomatosis.

10 operable bowel obstruction due to peritoneal carcinomatosis.

11 highly effective way to suppress peritoneal carcinomatosis.

12 d has shown clinical promise against ovarian carcinomatosis.

13 eports of high rates of local recurrence and carcinomatosis.

14 setting of hepatic metastases and peritoneal carcinomatosis.

15 the therapeutic index of IPC for peritoneal carcinomatosis.

16 ntional imaging in the staging of peritoneal carcinomatosis.

17 and the subsequent development of peritoneal carcinomatosis.

18 (SW620) were used as a model for peritoneal carcinomatosis.

19 and treating human patients with peritoneal carcinomatosis.

20 for the diagnosis or treatment of peritoneal carcinomatosis.

21 d complement the diagnosis of leptomeningeal carcinomatosis.

22 Patient 2 presented with peritoneal carcinomatosis and died after palliative surgery.

23 errantly activated Stat3 signaling in breast carcinomatosis and malignancies.

24 trast MR imaging enabled better detection of carcinomatosis and tumors less than 1 cm in diameter (75

25 stage-dependent local recurrence, peritoneal carcinomatosis, and lung metastasis.

26 for "nonclassical" indications (peritonitis, carcinomatosis, and so on) (P < 0.0001).

27 As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases.

28 tients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no sur

29 mic chemotherapy on patients with colorectal carcinomatosis before a curative procedure.

30 an cancer frequently present with peritoneal carcinomatosis, but the mechanisms that induce naive per

31 Peritoneal carcinomatosis can be difficult to diagnose, as CT is in

32 e survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC).

33 nei (PMP) is an uncommon peritoneal mucinous carcinomatosis confined to the peritoneal cavity.

34 breast cancer diagnosed with leptomeningeal carcinomatosis, CSF samples were subjected to a two-step

35 after complete CRS of colorectal peritoneal carcinomatosis, followed by IPC, in selected patients is

36 R) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001).

37 malignant bowel obstruction from peritoneal carcinomatosis from any primary malignant neoplasm and e

38 motherapy alone, the treatment of peritoneal carcinomatosis from colorectal cancer (CRPC) is still a

39 In the past, carcinomatosis from colorectal cancer was determined to

40 al chemotherapy for patients with peritoneal carcinomatosis from colorectal carcinoma remains to be e

41 ed with systemic chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.

42 y, leading to significant suppression of the carcinomatosis in both animal models.

43 ole of (18)F-FDG PET in detecting peritoneal carcinomatosis in patients with stomach, ovarian, and ad

44 In all, 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstructi

45 Peritoneal carcinomatosis is a common presentation in patients with

46 Peritoneal carcinomatosis is a major source of morbidity and mortal

47 Although leptomeningeal carcinomatosis is a well-established clinical syndrome,

48 the sensitivity of both in the detection of carcinomatosis is limited.

49 Meningeal carcinomatosis (MC) is a rare complication associated wi

50 rn of metastasis corresponds to lymphangitic carcinomatosis metastatic phenotype in human cancer pati

51 urface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enr

52 to open surgery without an increased risk of carcinomatosis or port site recurrence.

53 Peritoneal carcinomatosis (PC) from colorectal cancer may be treate

54 r cytoreductive surgery (CRS) for peritoneal carcinomatosis (PC) in a tertiary center.

55 of the radiological extent of the peritoneal carcinomatosis (PC) or the clinical examination; and sec

56 (LM) in patients with colorectal peritoneal carcinomatosis (PC) who underwent complete cytoreductive

57 eal cavity - a condition known as peritoneal carcinomatosis (PC).

58 py treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001)

59 nt ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC).

60 h which SPARC ameliorates peritoneal ovarian carcinomatosis seems to be multifaceted and has yet to b

61 tients which were classified as lymphangitic carcinomatosis showed high levels of VEGF-C expression i

62 uzumab treatment of patients with peritoneal carcinomatosis showed little agent-related toxicity, con

63 local recurrence, port site recurrence, and carcinomatosis that can occur with these aggressive tumo

64 st that SPARC ameliorates ovarian peritoneal carcinomatosis through abrogation of the initial steps o

65 In mice, peritoneal carcinomatosis use C57Bl/6 was induced in C57Bl/6 by int

66 Bandicoot papillomatosis carcinomatosis virus type 1 (BPCV1) is associated with p

67 to mouse ovaries and establishes peritoneal carcinomatosis, was used to evaluate the cooperative eff

68 ice), ascites production and intraperitoneal carcinomatosis were detected 3 to 7 weeks after SKOV-3 i

69 g intravenously) to patients with peritoneal carcinomatosis who had failed standard therapies.

70 ainst p53-deficient nude mouse-human ovarian carcinomatosis xenografts.